Abbott India is currently trading at Rs. 27700.00, up by 328.60 points or 1.20% from its previous closing of Rs. 27371.40 on the BSE.
The scrip opened at Rs. 27296.40 and has touched a high and low of Rs. 27700.00 and Rs. 27296.40 respectively. So far 16 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 30499.90 on 30-Aug-2024 and a 52 week low of Rs. 21983.40 on 21-Dec-2023.
Last one week high and low of the scrip stood at Rs. 28253.70 and Rs. 27159.70 respectively. The current market cap of the company is Rs. 58162.31 crore.
The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 9.16% and 15.85% respectively.
Abbott India has launched its Pneumococcal Conjugate Vaccine, PneumoShield 14, for children over 6 weeks of age. Abbott’s PCV-14 valent (Pneumococcal Conjugate Vaccine), offers broad protection, covering the highest number of serotypes, or strains, as compared to existing PCV-10 and PCV-13 vaccines.
A strain refers to a genetic or structural variant or subtype of a microorganism. The PCV-14 terminology in Abbott’s PneumoShield 14 vaccine refers to the fact that this vaccine offers protection against 14 different strains of pneumococcal bacteria. A conjugate vaccine is a distinct type of vaccine that combines a part of the bacteria with a protein to make it work better. This helps the immune system recognize and fight off the bacteria more effectively, making it stronger against certain infections, which can result in severe diseases, especially among children.
Abbott India is one of the leading multinational pharmaceutical companies in India and operates with owned manufacturing units and various independent contract/third party manufacturers based across the country. The company sells its products through independent distributors primarily within India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1800.30 |
| Dr. Reddys Lab | 1275.05 |
| Cipla | 1472.05 |
| Lupin | 2098.70 |
| Zydus Lifesciences | 979.10 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
